Now Approved: U.S. FDA approves product to reduce the incidence of catheter-related bloodstream infections (CRBSIs) under special pathway for patients receiving hemodialysis.

Learn more

Press releases

Here you can find corporate releases on topics related to governance, investments, and important announcements.

Read more

Investors

Nasdaq:

CRMD

$ 3.55 Last update: 12/07/2023 5:49:47 am ET Time Read more

About CRBSI

Learn more about Catheter-related blood stream infections (CRBSIs) and how they affect hemodialysis central venous catheter (HD-CVC) patients.

Read more
WHY CORMEDIX

We relentlessly pursue therapeutic options to reduce and treat infectious and inflammatory disease

About us
PRESS RELEASES

Review corporate releases related to governance,
investor news, and other important announcements.

Dec 04, 2023

CORMEDIX INC. ANNOUNCES PARTNERSHIP WITH THE LEAPFROG GROUP
Nov 15, 2023

CORMEDIX INC. ANNOUNCES FDA APPROVAL OF DEFENCATH® TO REDUCE THE INCIDENCE OF CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT HEMODIALYSIS PATIENTS
Nov 14, 2023

CORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Nov 06, 2023

CORMEDIX INC. TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 14, 2023
Sep 26, 2023

CORMEDIX INC. TO PRESENT AT THE CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE
See all